"Since the beginning of 2020 until now, the global wide spread of Covid–19 is a fluid and challenging situation facing all the industries. The Company has taken all possible effective measures to limit and keep the impact of Covid-19 under control in order to ensure business continuity with minimal disruption. The Company, as per business plans, is in the process of evaluating various sources of raising funds for its operations. The Company has also received a financial support letter from its parent Company which is valid till time the Company is able to raise funds from external sources. The Company will continue to pay close attention to the development of Covid–19, and will further evaluate and actively respond to such impact on the financial position and financial performance of the Company," it said in a statement.
SPARC's sister firm, Sun Pharma, too, was trading 1 per cent higher at Rs 534 apiece on the BSE. It hit an intra-day high of Rs 538 per share. For the June quarter, Sun Pharma
had posted a surprise consolidated loss of Rs 1,655.60 crore due to exceptional items of Rs 3,633.33 crore. It's profit was Rs 1,387.48 crore in the year-ago period.
"The exceptional items include unit Taro’s payment of $213.3 million (Rs 1,617.96 crore) to resolve all claims related to federal healthcare programs, as it resolved all matters with Department of Justice (DoJ), and unit Dusa’s settlement with DoJ to the tune of Rs 156.36 crore," it said in a statement.
It also said Taro has made certain provisions amounting to $60 million(Rs 455.19 crore) for related ongoing multi-jurisdiction civil antitrust matters, and added the ultimate outcome of the antitrust matters cannot be predicted with certainty.
The company’s revenues from operations stood at Rs 7,467.19 crore, down from Rs 8,259.30 crore a year ago.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.